A randomized, Phase 3, double-blind study of radiochemotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- AZ Sint-Lucas, Gent
- UZ Leuven, Leuven
- GZA campus Sint-Augustinus, Antwerpen
- OLV Aalst, Aalst
- CHU Ambroise Paré, Mons
- UZA, Antwerpen
